StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $5.02 | $4.73 | -5.78% | 0.2M |
| 05-12 | $4.74 | $4.79 | +1.05% | 0.2M |
| 05-13 | $4.66 | $4.83 | +3.65% | 0.1M |
| 05-14 | $4.90 | $5.22 | +6.53% | 0.2M |
| 05-15 | $5.29 | $4.90 | -7.37% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2019 2019-12-31 | Q3 2019 2019-09-30 | Q2 2019 2019-06-30 |
|---|---|---|---|
Revenue | $165.00K | $165.00K | $165.00K |
Operating Income | $-26.70M | $-17.20M | $-8.72M |
Net Income | $-23.84M | $-15.10M | $-5.30M |
EPS (Diluted) | Not available | Not available | Not available |
Total Assets | $139.42M | Not available | Not available |
Total Liabilities | $17.80M | Not available | Not available |
Cash & Equivalents | $61.08M | Not available | Not available |
Free Cash Flow OCF − CapEx | $-20.49M | $-11.51M | $-5.11M |
Shares Outstanding | 2.10M | Not available | Not available |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.